Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:ZEAL

Zealand Pharma A/S (ZEAL) Stock Price, News & Analysis

Zealand Pharma A/S logo

About Zealand Pharma A/S Stock (NASDAQ:ZEAL)

Key Stats

Today's Range
$17.59
$17.59
50-Day Range
$16.54
$19.20
52-Week Range
$9.93
$32.94
Volume
N/A
Average Volume
4,965 shs
Market Capitalization
$818.60 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
Buy

Company Overview

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company markets lixisenatide under the brand names of Adlyxin and Lyxumia; Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia, congenital hyperinsulinism, and post bariatric surgery hypoglycemia; and Dasiglucagon dual-hormone artificial pancreas for automated diabetes management. The company's pipeline includes Dasiglucagon that is in Phase III clinical trials for congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. Zealand Pharma A/S has collaboration agreements with Sanofi-Aventis Deutschland GmbH; Boehringer Ingelheim International GmbH; Alexion Pharmaceuticals, Inc.; and Beta Bionics, Inc. The company was incorporated in 1998 and is headquartered in Copenhagen, Denmark.

Receive ZEAL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Zealand Pharma A/S and its competitors with MarketBeat's FREE daily newsletter.

ZEAL Stock News Headlines

Trump won. Buy this coin now.
Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will go to $150,000 — or more. But there’s one coin he thinks could go even higher.
See More Headlines

ZEAL Stock Analysis - Frequently Asked Questions

Zealand Pharma A/S (NASDAQ:ZEAL) posted its quarterly earnings results on Wednesday, November, 10th. The company reported ($4.61) earnings per share for the quarter, beating the consensus estimate of ($6.31) by $1.70. The firm earned $16.87 million during the quarter, compared to the consensus estimate of $12.21 million. Zealand Pharma A/S had a negative net margin of 565.44% and a negative trailing twelve-month return on equity of 111.04%.

Zealand Pharma A/S (ZEAL) raised $75 million in an initial public offering (IPO) on Wednesday, August 9th 2017. The company issued 3,900,000 shares at a price of $19.30 per share. Morgan Stanley and Goldman Sachs acted as the underwriters for the IPO and Guggenheim Securities and Needham & Company were co-managers.

Based on aggregate information from My MarketBeat watchlists, some other companies that Zealand Pharma A/S investors own include Sorrento Therapeutics (SRNE), NVIDIA (NVDA), Vertex Pharmaceuticals (VRTX), Editas Medicine (EDIT), Spectrum Pharmaceuticals (SPPI), AbbVie (ABBV) and CRISPR Therapeutics (CRSP).

Company Calendar

Last Earnings
11/10/2021
Today
11/21/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ZEAL
Employees
355
Year Founded
N/A

Profitability

Net Income
$-161,990,000.00
Net Margins
-565.44%
Pretax Margin
-364.34%

Debt

Sales & Book Value

Annual Sales
$46.54 million
Book Value
$3.38 per share

Miscellaneous

Free Float
45,514,000
Market Cap
$818.60 million
Optionable
Not Optionable
Beta
1.45
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

This page (NASDAQ:ZEAL) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners